Michelle Finney

Summary

Affiliation: Health Protection Agency
Country: UK

Publications

  1. ncbi Antimicrobial effects of a novel Triclosan/zinc citrate dentifrice against mixed culture oral biofilms
    Michelle Finney
    Health Protection Agency, Porton Down, Centre for Applied Microbiology and Research, Salisbury SP4 0JG, UK
    Int Dent J 53:371-8. 2003
  2. ncbi Characterization of the key antigenic components and pre-clinical immune responses to a meningococcal disease vaccine based on Neisseria lactamica outer membrane vesicles
    Michelle Finney
    Health Protection Agency, Centre for Emergency Preparedness and Response, Porton Down, Salisbury, UK
    Hum Vaccin 4:23-30. 2008
  3. ncbi Phase I safety and immunogenicity study of a candidate meningococcal disease vaccine based on Neisseria lactamica outer membrane vesicles
    Andrew R Gorringe
    Health Protection Agency, Centre for Emergency Preparedness and Response, Porton Down, Salisbury, UK
    Clin Vaccine Immunol 16:1113-20. 2009
  4. ncbi The development of a meningococcal disease vaccine based on Neisseria lactamica outer membrane vesicles
    Andrew Gorringe
    Health Protection Agency, Porton Down, Salisbury SP4 0JG, UK
    Vaccine 23:2210-3. 2005

Detail Information

Publications4

  1. ncbi Antimicrobial effects of a novel Triclosan/zinc citrate dentifrice against mixed culture oral biofilms
    Michelle Finney
    Health Protection Agency, Porton Down, Centre for Applied Microbiology and Research, Salisbury SP4 0JG, UK
    Int Dent J 53:371-8. 2003
    ..To compare the antimicrobial efficacy in vitro of a new fluoride system containing 0.3% Triclosan and 2.0% zinc citrate with a standard fluoride toothpaste against bacteria commonly isolated from dental plaque...
  2. ncbi Characterization of the key antigenic components and pre-clinical immune responses to a meningococcal disease vaccine based on Neisseria lactamica outer membrane vesicles
    Michelle Finney
    Health Protection Agency, Centre for Emergency Preparedness and Response, Porton Down, Salisbury, UK
    Hum Vaccin 4:23-30. 2008
    ..However, such antisera did mediate opsonophagocytosis, suggestingthat this may did mediate opsonophagocytosis, suggesting that this may be a mechanism by which this vaccine protects in a mouse model of meningococcal bacteraemia...
  3. ncbi Phase I safety and immunogenicity study of a candidate meningococcal disease vaccine based on Neisseria lactamica outer membrane vesicles
    Andrew R Gorringe
    Health Protection Agency, Centre for Emergency Preparedness and Response, Porton Down, Salisbury, UK
    Clin Vaccine Immunol 16:1113-20. 2009
    ..In conclusion, this N. lactamica OMV vaccine is safe and induces a weak but broad humoral immune response to N. meningitidis...
  4. ncbi The development of a meningococcal disease vaccine based on Neisseria lactamica outer membrane vesicles
    Andrew Gorringe
    Health Protection Agency, Porton Down, Salisbury SP4 0JG, UK
    Vaccine 23:2210-3. 2005
    ..The vaccine is currently being manufactured and validated ELISA protocols have been developed for the analysis of serological responses...